Emcure Pharmaceuticals has significantly reduced the price of its weight management drug, Poviztra, to ₹3,999 per month, effective April 3, 2026. This decision comes in the wake of Novo Nordisk’s semaglutide patent expiration in India, which has spurred increased competition within the weight loss drug market.
The price cut reflects Emcure’s strategy to maintain its market position amidst new entrants and generic versions of semaglutide medications. Semaglutide, originally developed by Novo Nordisk, is a glucagon-like peptide-1 (GLP-1) receptor agonist used for treating type 2 diabetes and, increasingly, for weight management.
With the expiration of the patent, several Indian pharmaceutical companies are now able to produce and market semaglutide-based drugs, intensifying competition and driving down prices. This benefits consumers by making weight management treatments more accessible and affordable.
Industry analysts note that Emcure’s proactive price adjustment is a strategic move to retain market share and attract price-sensitive consumers. The dynamics of the Indian pharmaceutical market are expected to shift further as more companies introduce their versions of semaglutide drugs.
The reduction in price could also impact Novo Nordisk’s market strategy in India, potentially requiring them to adjust their pricing or marketing approaches to compete effectively. The long-term effects will depend on how other players in the market respond to these changes.
This development highlights the increasing competition and affordability in the Indian pharmaceutical sector, particularly in therapeutic areas with expiring patents. Patients and healthcare providers now have more options, which could lead to better health outcomes and increased access to essential medications.
About the Author
